Clinical Trial Update: Relative Bioavailability Study of Two Montelukast Sodium (GW483100) 5 Milligrams (mg) Chewable Tablets and One Reference Montelukast Sodium 5 mg Chewable Tablet in Healthy Adult Subjects [Phase 1]

View source ↗

Summary

A Phase 1 relative bioavailability study comparing two Montelukast sodium 5 mg chewable tablets to a reference 5 mg Montelukast chewable tablet in healthy adult…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis
• Asthma
• Exercise-induced Bronchoconstriction

Drugs mentioned

• Montelukast sodium chewable tablet (Montelukast)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Respiratory Disorders | Phase 1 | Status: COMPLETED